Stem Cells Bank SA - Sistemul Medical Medlife

Stem Cells Bank is a cord blood bank in Timisoara, Romania, created in 2010 and offering stem cell storage services in Romania and the neighbouring countries. The company has set up an advanced biotechnology laboratory, operating under the strictest European and national regulations. Stem Cells Bank is open to partnerships regarding stem cells banking, applications and biotechnology services in general.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ARCTIC VISION ANNOUNCES US$32MN IN SERIES A TO EXPAND INNOVATIVE PRODUCT PORTFOLIO IN OPHTHALMOLOGY

Arctic Vision | July 15, 2020

news image

Arctic Vision, a clinical-stage biotechnology company incubated by Nan Fung Life Sciences and Pivotal BioVenture Partners China in 2019, today announced its $32mn Series A financing led by Morningside Ventures, together with its existing investors. Arctic Vision focuses on the development and commercialization of innovative ophthalmology therapies in China and Asia. The three investment institutions are actively investing in leading life science companies in the world with long term commitment.&...

Read More

INDUSTRIAL IMPACT

BICYCLE THERAPEUTICS ANNOUNCES EXPANSION OF GENENTECH IMMUNO-ONCOLOGY COLLABORATION

Bicycle Therapeutics | October 26, 2021

news image

Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that Genentech, a member of the Roche Group, has exercised an option to initiate a new program, expanding the exclusive strategic collaboration agreement with Bicycle to discover, develop and commercialize novel Bicycle®-based immuno-oncology therapies. Bicycle and Genentech are collabora...

Read More

EMERGENT BIOSOLUTIONS ANNOUNCES INITIATION OF PHASE 3 CINICAL TRIAL OF HYPERIMMUNE INTRAVENOUS IMMUNOGLOBULIN TO TREAT COVID-19 PATIENTS

Emergent BioSolutions | October 09, 2020

news image

NIAID has initiated a Phase 3 clinical trial to evaluate the safety, tolerability, and efficacy of hyperimmune globulin products, including Emergent’s COVID-19 Human Immune Globulin (COVID-HIG), as a potential treatment in adult patients hospitalized with COVID-19. Emergent is planning additional clinical trials to evaluate COVID-HIG for potential use in other patient populations or individuals at high risk of exposure. Emergent BioSolutions, Inc. Inc. (NYSE:EBS) today announced the initia...

Read More

CELL AND GENE THERAPY

X-THERMA CLOSES OVERSUBSCRIBED $13M SERIES A FINANCING LED BY LOREA AG

X-Therma Inc. | December 23, 2021

news image

X-Therma Inc., a biotechnology company developing breakthrough technology for regenerative medicine and organ preservation - has closed an oversubscribed $13M Series A funding round. The financing is led by LOREA AG, an entrepreneur-operated investment firm, with participation from Zen11 Holdings, Graphene Ventures, VU Venture Partners, 2b AHEAD Ventures, Methuselah Foundation, Catalytic Impact Foundation, along with notable return angel investors. X-Therma’s technology, a n...

Read More
news image

ARCTIC VISION ANNOUNCES US$32MN IN SERIES A TO EXPAND INNOVATIVE PRODUCT PORTFOLIO IN OPHTHALMOLOGY

Arctic Vision | July 15, 2020

Arctic Vision, a clinical-stage biotechnology company incubated by Nan Fung Life Sciences and Pivotal BioVenture Partners China in 2019, today announced its $32mn Series A financing led by Morningside Ventures, together with its existing investors. Arctic Vision focuses on the development and commercialization of innovative ophthalmology therapies in China and Asia. The three investment institutions are actively investing in leading life science companies in the world with long term commitment.&...

Read More
news image

INDUSTRIAL IMPACT

BICYCLE THERAPEUTICS ANNOUNCES EXPANSION OF GENENTECH IMMUNO-ONCOLOGY COLLABORATION

Bicycle Therapeutics | October 26, 2021

Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that Genentech, a member of the Roche Group, has exercised an option to initiate a new program, expanding the exclusive strategic collaboration agreement with Bicycle to discover, develop and commercialize novel Bicycle®-based immuno-oncology therapies. Bicycle and Genentech are collabora...

Read More
news image

EMERGENT BIOSOLUTIONS ANNOUNCES INITIATION OF PHASE 3 CINICAL TRIAL OF HYPERIMMUNE INTRAVENOUS IMMUNOGLOBULIN TO TREAT COVID-19 PATIENTS

Emergent BioSolutions | October 09, 2020

NIAID has initiated a Phase 3 clinical trial to evaluate the safety, tolerability, and efficacy of hyperimmune globulin products, including Emergent’s COVID-19 Human Immune Globulin (COVID-HIG), as a potential treatment in adult patients hospitalized with COVID-19. Emergent is planning additional clinical trials to evaluate COVID-HIG for potential use in other patient populations or individuals at high risk of exposure. Emergent BioSolutions, Inc. Inc. (NYSE:EBS) today announced the initia...

Read More
news image

CELL AND GENE THERAPY

X-THERMA CLOSES OVERSUBSCRIBED $13M SERIES A FINANCING LED BY LOREA AG

X-Therma Inc. | December 23, 2021

X-Therma Inc., a biotechnology company developing breakthrough technology for regenerative medicine and organ preservation - has closed an oversubscribed $13M Series A funding round. The financing is led by LOREA AG, an entrepreneur-operated investment firm, with participation from Zen11 Holdings, Graphene Ventures, VU Venture Partners, 2b AHEAD Ventures, Methuselah Foundation, Catalytic Impact Foundation, along with notable return angel investors. X-Therma’s technology, a n...

Read More